Regenerex Pharma auditor resigns after 9 years
Regenerex Pharma’s long‑time auditor resigned effective August 31, 2026, as the company continues to face going‑concern disclosures and works to catch up on delayed SEC filings.
Rhea-AI Filing Summary
REGENEREX PHARMA, INC. (RGPX) reports that its independent registered public accounting firm, dbbmckennon, resigned effective August 31, 2026, after serving in that role since 2017. The board acknowledged and accepted the firm’s internal decision to cease providing services.
dbbmckennon’s reports on the company’s financial statements for the fiscal years ended March 31, 2025 and December 31, 2025 contained no adverse or disclaimed opinions and were not qualified, but did include an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern, and for the April 1–December 31, 2025 transition period also noted a revision to disclose related party transactions. The company states there were no disagreements or reportable events with dbbmckennon under Regulation S‑K and is in the process of engaging a successor auditor while working to complete outstanding periodic reports and bring its SEC filings current.
Positive
- None.
Negative
- Auditor resignation: Long‑time independent auditor dbbmckennon resigned effective August 31, 2026, creating near‑term uncertainty around the audit function until a successor firm is engaged.
- Going‑concern uncertainty: Prior audit reports included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern.
- Delayed SEC reporting: The company discloses it is still working to complete outstanding periodic reports and to bring its SEC filings current.
8-K Event Classification
2 items: 4.01, 9.01
2 items
Item 4.01
Changes in Registrant's Certifying Accountant
Governance
The company changed its independent auditing firm, which may involve disagreements on accounting matters.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Auditor resignation effective date: August 31, 2026
Fiscal year end: March 31, 2025
Fiscal year end: December 31, 2025
+2 more
5 metrics
Auditor resignation effective date
August 31, 2026
Date dbbmckennon ceased serving as independent registered public accounting firm
Fiscal year end
March 31, 2025
One of the two most recent fiscal years covered by dbbmckennon’s report
Fiscal year end
December 31, 2025
Transition period end and audited year with going-concern explanatory paragraph
Auditor tenure start
2017
Year dbbmckennon began serving as the company’s independent registered public accounting firm
Transition period
April 1, 2025 to December 31, 2025
Period for which the auditor noted a revision to disclose related party transactions
Key Terms
independent registered public accounting firm, going concern, reportable events, Emerging growth company, +1 more
5 terms
independent registered public accounting firm regulatory
"had been serving as the independent registered public accounting firm of Regenerex"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
going concern financial
"included an explanatory paragraph related to substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
reportable events regulatory
"there were no “reportable events,” as defined in Item 304(a)(1)(v) of Regulation S-K"
Reportable events are significant incidents or changes a company is legally required to disclose to regulators and the public, such as major safety problems, legal actions, financial irregularities, or management changes. They matter to investors because these events can alter a company’s risk profile or future performance, much like a dashboard warning light signals a problem that could affect a car’s safety or reliability. Timely disclosure helps investors make informed decisions and maintain market fairness.
Emerging growth company regulatory
"Emerging growth company [X]"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What change in auditor did RGPX disclose in this Form 8-K?
Regenerex Pharma, Inc. disclosed that dbbmckennon resigned as its independent registered public accounting firm, effective August 31, 2026, after serving in that role since 2017.
Did Regenerex Pharma (RGPX) report any disagreements with its former auditor?
No. The company states there were no disagreements with dbbmckennon on accounting principles, financial statement disclosure, or audit scope or procedures during the two most recent fiscal years.
What going-concern disclosure affects Regenerex Pharma (RGPX)?
Audit reports for the fiscal years ended March 31, 2025 and December 31, 2025 included an explanatory paragraph raising substantial doubt about Regenerex Pharma’s ability to continue as a going concern.
Were there any reportable events under Regulation S-K for RGPX?
The company reports that during its two most recent fiscal years there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S‑K in relation to dbbmckennon.
Is Regenerex Pharma (RGPX) current with its SEC filings?
No. Regenerex Pharma states it is continuing efforts to complete its outstanding periodic reports and to bring its SEC filings current, working with its future successor auditor.
Has Regenerex Pharma (RGPX) chosen a new auditor yet?
Not yet. The company states it is in the process of engaging a successor independent registered public accounting firm and intends to complete the engagement as promptly as practicable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
